Log in to your Inderes Free account to see all free content on this page.
Annexin Pharmaceuticals
14.50 SEK
+1.40 %
Less than 1K followers
ANNX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Annexin Pharmaceuticals
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 57.71 | 87.58 | 55.67 | 55.56 | 23.89 | 42.28 | 19.80 |
| Shares | 0.5 | 1.4 | 2.5 | 2.8 | 1.8 | 5.5 | 7.1 |
| Market cap | 31.1 | 125.2 | 137.2 | 154.2 | 43.4 | 230.8 | 139.8 |
| Enterprise value | 27.1 | 107.1 | 87.8 | - | - | - | - |
| EV/S | - | - | - | - | - | - | - |
| EV/EBITDA | neg. | neg. | neg. | - | - | - | - |
| EV/EBIT | neg. | neg. | neg. | - | - | - | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 2.71 | 6.07 | 2.94 | 5.11 | 2.31 | 16.83 | 5.61 |
| P/S | - | - | - | - | - | - | - |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 71.6 % | 82.0 % | 88.5 % | 82.2 % | 70.3 % | 72.0 % | 82.7 % |
| Gearing ratio | 2.0 % | - | - | - | - | - | - |
Login required
This content is only available for logged in users